After Cancer
This page exists because the supplement category has been silent about your cohort and the silence has not been an accident. The safety hedging is real, the literature is thinner than the literature on non-clinical menopause, and the marketing math is unkind to a brand that does the work of saying "this may not be the right product for you." We are doing the work anyway.
What is in the Honey Stick
Three botanicals at disclosed clinical doses:
- Shatavari (Asparagus racemosus) — 80 mg, standardized root extract
- Saffron (Crocus sativus) — standardized extract, dose disclosed on the supplement facts panel
- Shilajit (fulvic mineral complex) — 300 mg, third-party tested for heavy metals
Delivered sublingually in 8 g of strawberry honey. No estrogen, no progesterone, no testosterone, no proprietary blends.
Bloom may not be right for you if…
You are currently receiving active treatment for any cancer and have not yet discussed botanical supplements with your oncology team. The conversation has to happen first. We are not the team that can have it for you, and we are not interested in pretending otherwise.
You are on Tamoxifen or an aromatase inhibitor and are uncertain whether shatavari interacts with your protocol. The literature does not show estrogen-replacement activity at the dose in this formula, but the surveillance posture matters and the question is for your oncologist, not for our marketing copy.
You are on chemotherapy or a Lupron protocol. Sublingual absorption of any botanical during chemotherapy is a conversation with your oncology team, full stop.
Bloom may be right for you if…
You have finished active treatment for a non-hormonal cancer and your menopausal symptoms are the residual cost of chemotherapy or radiation. You have a hormone-sensitive cancer history and your oncologist has cleared non-hormonal supplements after reviewing the formula. You have BRCA-positive status and chose prophylactic oophorectomy and now live in a surgical menopause your gynecologist did not warn you about adequately.
Bring this to your oncologist
Print this page. Bring it. The dose table above is the entire material disclosure. The cited evidence on each active — Pingali 2024 Cureus for shatavari; Hausenblas 2013 + Kashani 2022 for saffron; Pingali 2022 Phytomedicine + Mosavi 2023 for shilajit — is on our science page with full PubMed links.
We will not tell you this is safe for you. We will tell you what is in it, what the evidence is, and what we ask you to ask before you start. That is the Stage 5 move the rest of the category has not made.
For ongoing email updates as the After Cancer literature evolves — sourced from real oncology publications, not marketing — drop your address below.